Indivior (NASDAQ:INDV) Shares Up 3%

Indivior PLC (NASDAQ:INDV)’s stock price was up 3% on Monday . The stock traded as high as $19.89 and last traded at $19.89. Approximately 134,288 shares were traded during trading, an increase of 12% from the average daily volume of 120,170 shares. The stock had previously closed at $19.32.

Analyst Ratings Changes

Separately, Craig Hallum started coverage on Indivior in a research note on Wednesday, April 3rd. They issued a “buy” rating and a $37.00 target price for the company.

Indivior Trading Up 0.2 %

The company’s fifty day moving average is $20.38 and its 200-day moving average is $18.41.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Thursday, February 22nd. The company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.15. The business had revenue of $293.00 million during the quarter, compared to analyst estimates of $260.00 million. Indivior had a return on equity of 538.18% and a net margin of 0.18%. As a group, analysts forecast that Indivior PLC will post 2.03 EPS for the current year.

Hedge Funds Weigh In On Indivior

Several institutional investors have recently made changes to their positions in INDV. Scopia Capital Management LP acquired a new stake in Indivior during the third quarter valued at $191,743,000. Vanguard Group Inc. boosted its stake in shares of Indivior by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 5,899,190 shares of the company’s stock worth $90,081,000 after acquiring an additional 52,836 shares in the last quarter. FMR LLC grew its position in shares of Indivior by 53.5% during the 3rd quarter. FMR LLC now owns 5,498,087 shares of the company’s stock valued at $119,339,000 after acquiring an additional 1,915,980 shares during the period. Goldman Sachs Group Inc. purchased a new position in shares of Indivior in the 2nd quarter valued at about $83,678,000. Finally, Barclays PLC raised its holdings in Indivior by 746.6% in the 4th quarter. Barclays PLC now owns 3,093,161 shares of the company’s stock worth $47,232,000 after purchasing an additional 2,727,791 shares during the period. 60.33% of the stock is owned by hedge funds and other institutional investors.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.